Nasdaq3d
Regeneron and Truveta Announce Strategic Collaboration for the Truveta Genome Project, Aiming to Expand Genetic Database and Accelerate Drug Discovery
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...
Nasdaq6d
Forecasting The Future: 22 Analyst Projections For Regeneron Pharmaceuticals
During the last three months, 22 analysts shared their evaluations of Regeneron Pharmaceuticals (NASDAQ:REGN), revealing diverse outlooks from bullish to bearish. Summarizing their recent ...
Nasdaq3d
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?
To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose ...
Nasdaq10d
Decoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture?
Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened ...
Nasdaq14d
Regeneron Pharmaceuticals Unusual Options Activity
Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:REGN) revealed 10 unusual trades. Delving into the details, we found 30% of traders were bullish, while 50% showed bearish ...
Nasdaq3d
Regeneron To Invest $119.5 Mln In Truveta's Financing Round, Launch Truveta Genome Project
In the pre-market hours, Regeneron's stock is trading at $695, down 0.27 percent on the Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not ...
Nasdaq3d
Regeneron Pharma Reports Positive Results From C-POST Trial With Libtayo - Quick Facts
(RTTNews) - Regeneron Pharmaceuticals ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Nasdaq28d
Regeneron Pharmaceuticals Reports Positive Phase 2 Results for Antithrombotic Antibodies REGN7508 and REGN9933 Targeting Factor XI
TARRYTOWN, N.Y., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct ...
Nasdaq14d
1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street
Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) started 2024 on a strong note and performed well through the first half of the year. However, the drugmaker has since seen its shares decline ...
UBS cuts rating on Regeneron stock amid Eylea uncertainty
UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.
Regeneron Pharmaceuticals, Inc. Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the REGN Class Action
SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’
We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...